Stability and CTL activity of N-terminal glutamic acid containing peptides.
Several cytotoxic T lymphocyte peptide-based vaccines against hepatitis B, human immunodeficiency virus and melanoma were recently studied in clinical trials. One interesting melanoma vaccine candidate alone or in combination with other tumor antigens, is the decapeptide ELA. This peptide is a Melan-A/MART-1 antigen immunodominant peptide analog, with an N-terminal glutamic acid. It has been reported that the amino group and gamma-carboxylic group of glutamic acids, as well as the amino group and gamma-carboxamide group of glutamines, condense easily to form pyroglutamic derivatives. To overcome this stability problem, several peptides of pharmaceutical interest have been developed with a pyroglutamic acid instead of N-terminal glutamine or glutamic acid, without loss of pharmacological properties. Unfortunately compared with ELA, the pyroglutamic acid derivative (PyrELA) and also the N-terminal acetyl-capped derivative (AcELA) failed to elicit cytotoxic T lymphocyte (CTL) activity. Despite the apparent minor modifications introduced in PyrELA and AcELA, these two derivatives probably have lower affinity than ELA for the specific class I major histocompatibility complex. Consequently, in order to conserve full activity of ELA, the formation of PyrELA must be avoided. Furthermore, this stability problem is worse in the case of clinical grade ELA, produced as an acetate salt, like most of the pharmaceutical grade peptides. We report here that the hydrochloride salt, shows higher stability than the acetate salt and may be suitable for use in man. Similar stability data were also obtained for MAGE-3, another N-terminal glutamic acid containing CTL peptide in clinical development, leading us to suggest that all N-terminal glutamic acid and probably glutamine-containing CTL peptide epitopes may be stabilized as hydrochloride salts.
Beck
A
A
Centre d'Immunologie Pierre Fabre (CIPF), Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com
Bussat
M C
MC
Klinguer-Hamour
C
C
Goetsch
L
L
Aubry
J P
JP
Champion
T
T
Julien
E
E
Haeuw
J F
JF
Bonnefoy
J Y
JY
Corvaia
N
N
D000818:Animals; D000837:Anion Exchange Resins; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines / Q000276:immunology; D002460:Cell Line / Q000276:immunology / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D002857:Chromium / Q000378:metabolism; D018984:Epitopes, T-Lymphocyte; D018698:Glutamic Acid / Q000737:chemistry*; D006098:Granulocytes; D006801:Humans; D007114:Immunization; D007519:Isoantigens / Q000378:metabolism*; D008545:Melanoma / Q000276:immunology*; D051379:Mice; D009363:Neoplasm Proteins / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D010446:Peptide Fragments / Q000276:immunology*; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism; D021241:Spectrometry, Mass, Electrospray Ionization; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000837:Anion Exchange Resins; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; C531098:HNA-4A antigen; D007519:Isoantigens; C072013:MAGEA3 protein, human; C489519:Mageb3 protein, mouse; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D010455:Peptides; D002857:Chromium; D018698:Glutamic Acid